Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
ResMed (NYSE: RMD) has agreed to acquire Noctrix Health, a medical technology company specializing in neuromodulation therapies, for $340 million. The deal brings Noctrix’s lead product, Nidra, the first FDA-authorized non-invasive therapy for moderate-to-severe Restless Legs Syndrome, into ResMed’s portfolio.
Key figures
- Deal Value Usd
- 340000000
- Angelini series c investment
- 40000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.